(19)
(11) EP 2 331 530 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.12.2013 Bulletin 2013/52

(45) Mention of the grant of the patent:
21.08.2013 Bulletin 2013/34

(21) Application number: 09816751.3

(22) Date of filing: 22.09.2009
(51) International Patent Classification (IPC): 
C07D 403/12(2006.01)
A61K 31/4365(2006.01)
 C07D 401/12(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/US2009/057768
(87) International publication number:
WO 2010/036629 (01.04.2010 Gazette 2010/13)

(54)

FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

KONDENSIERTE MULTIZYKLISCHE VERBINDUNGEN ALS PROTEINKINASEHEMMER

COMPOSÉS MULTICYCLIQUES FUSIONNÉS EN TANT QU INHIBITEURS DES PROTÉINES KINASES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 26.09.2008 US 100490 P

(43) Date of publication of application:
15.06.2011 Bulletin 2011/24

(73) Proprietor: National Health Research Institutes
Taiwan (TW)

(72) Inventors:
  • HSIEH, Hsing-Pang
    Miaoli County 35053 (TW)
  • COUMAR, Selvaraj Mohane
    Moolakulam Pondicherry 605010 (IN)
  • CHAO, Yu-Sheng
    Nwe York New York, 10011 (US)

(74) Representative: Chajmowicz, Marion et al
Becker & Associés 25, rue Louis Le Grand
75002 Paris
75002 Paris (FR)


(56) References cited: : 
WO-A1-2007/013964
US-A1- 2004 242 883
 WO-A2-2006/080043
US-A1- 2006 035 908
   
  • OSLOB J D ET AL: "Discovery of a potent and selective Aurora kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 17, 1 September 2008 (2008-09-01), pages 4880-4884, XP024100122, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.07.073 [retrieved on 2008-07-24]
  • M. BAUSER ET AL.: 'Discovery and optimization of 2-aryl oxazolo-pyrimidines as adenosine kinase inhibitors using liquid phase parallel synthesis' BIOOR G.MED. CHEM. LETT. vol. 14, 2004, pages 1997 - 2000, XP008145571
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).